Synthorx

LA JOLLA, CA · Founded 2014 · Biotech · Acquired

Synthetic DNA with expanded genetic alphabet encoding modified IL-2 cytokine (THOR-707) for cancer immunotherapy

Claim this profile

Follows are private to you and power your alerts

Updated · synthorx.com

Sector
Biotech
Headquarters
LA JOLLA, CA
Founded
2014
Latest Form D
$26.5M, Apr 2018
Total capital
$34.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$34.7M
3 Form D · last Apr 2018
102 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
11
29 pending · first 2020
Rank in peer group#156 of 1449

Capital timeline

20142015201620172018FEDERAL ↑EQUITY ↓Cumulative $34.7M1st Form D$3.1M2nd Form D$5M3rd Form D$26.5M
20142015201620172018FEDERAL ↑EQUITY ↓Cumulative $34.7M2nd Form D$5M3rd Form D$26.5M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$26.5M
  • Private capital raisedForm D · SEC · 2nd filing$5M
  • Private capital raisedForm D · SEC · 1st filing$3.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#156 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Andrew LevinDirectorNamed in SEC Form D filings
  • Court TurnerExecutive Officer, DirectorNamed in SEC Form D filings
  • Douglas DownsExecutive OfficerNamed in SEC Form D filings
  • Floyd RomesbergDirectorNamed in SEC Form D filings
  • Jay LichterDirectorNamed in SEC Form D filings
  • Laura ShawverExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
  • Peter ThompsonDirectorNamed in SEC Form D filings
  • Tighe ReardonExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 40
Show all 40 patent records
  • Immuno Oncology Combination Therapy With IL-2 Conjugates And Anti-egfr AntibodiesApr 30, 2026 · Application 19305326Pending
  • IL-2 Conjugates and Methods of Use ThereofJan 13, 2026 · US 12,521,437Granted
  • Interleukin 10 Conjugates And Uses ThereofDec 9, 2025 · US 12,491,254Granted
  • Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesOct 23, 2025 · Application 19025471Pending
  • Cytokine Conjugates For The Treatment Of Autoimmune DiseasesOct 23, 2025 · Application 19257936Pending
  • Cytokine Conjugates For The Treatment Of Autoimmune DiseasesAug 5, 2025 · US 12,377,131Granted
  • Novel IL-15 Conjugates And Uses ThereofJul 1, 2025 · US 12,344,648Granted
  • Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesJun 3, 2025 · US 12,318,431Granted
  • IL-2 Conjugates and Methods of Use to Treat Autoimmune DiseasesMay 15, 2025 · Application 18886814Pending
  • Incorporation Of Unnatural Nucleotides And Methods ThereofMar 13, 2025 · Application 18955271Pending
  • Methods For Selecting Subjects And Treating Cancer With IL-2 TherapyMar 6, 2025 · Application 18727910Pending
  • IL-2 Conjugates And Methods Of Use To Treat Autoimmune DiseasesFeb 25, 2025 · US 12,234,271Granted
  • IL-15 Conjugates and Uses ThereofNov 21, 2024 · Application 18424573Pending
  • IL-15 Conjugates and Uses ThereofAug 29, 2024 · Application 18415445Pending
  • Head And Neck Cancer Combination Therapy Comprising An IL-2 Conjugate And CetuximabJul 11, 2024 · Application 18524157Pending
  • IL-15 Conjugates and Uses ThereofMar 5, 2024 · US 11,919,934Granted
  • Immuno Oncology Combination Therapy With IL-2 Conjugates And PembrolizumabSep 7, 2023 · Application 18296710Pending
  • Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesJul 18, 2023 · US 11,701,407Granted
  • Cytokine Conjugates For The Treatment Of Autoimmune DiseasesApr 11, 2023 · US 11,622,993Granted
  • Interleukin 10 Conjugates and Uses ThereofSep 1, 2022 · Application 17735564Pending
  • Immuno Oncology Combination Therapy With IL-2 Conjugates And Anti-egfr AntibodiesJan 20, 2022 · Application 17357615Pending
  • IL-2 Conjugates And Methods Of Use ThereofAug 3, 2021 · US 11,077,195Granted
  • Immuno Oncology Combination Therapies With IL-2 ConjugatesFeb 18, 2021 · Application 16993967Pending
  • IL-2 Conjugates And Methods Of Use ThereofAug 6, 2020 · Application 16783095Pending
  • Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesJun 11, 2020 · Application 16634479Pending
  • Cytokine Conjugates For The Treatment Of Proliferative And Infectious DiseasesApr 7, 2020 · US 10,610,571Granted
  • Incorporation Of Unnatural Nucleotides And Methods ThereofJan 23, 2020 · Application 16577347Pending
  • Incorporation Of Unnatural Nucleotides And Methods ThereofDec 28, 2017 · Application 15543217Pending
  • Lung Cancer Combination Therapy With IL-2 Conjugates And PembrolizumabApplication 63276954Pending
  • Skin Cancer Combination Therapy With IL-2 Conjugates And CemiplimabApplication 63276955Pending
  • Classic Hodgkin Lymphoma Combination Therapy With IL-2 Conjugates And PembrolizumabApplication 63291654Pending
  • Cancer Combination Therapy with IL-2 Conjugates and CetuximabApplication 63293139Pending
  • Methods For Selecting Subjects And Treating Cancer With IL-2 TherapyApplication 63299113Pending
  • Skin Cancer Combination Therapy With IL-2 Conjugates And CemiplimabApplication PCTUS2022016216Pending
  • Head And Neck Cancer Combination Therapy Comprising An IL-2 Conjugate And A PD-1 AntagonistApplication PCTUS2022031968Pending
  • Cancer Therapy With IL-2 Conjugates And Chimeric Antigen Receptor TherapiesApplication PCTUS2023085227Pending
  • Head And Neck Cancer Combination Therapy Comprising An IL-2 Conjugate And CetuximabApplication PCTUS2022031974Pending
  • Classic Hodgkin Lymphoma Combination Therapy With IL-2 Conjugates And An ANTI-PD-1 Antibody Or Antigen-binding Fragment ThereofApplication PCTUS2022081999Pending
  • Cancer Therapy With IL-2 Conjugates And Chimeric Antigen Receptor TherapiesApplication PCTUS2022082151Pending
  • Head And Neck Cancer Combination Therapy Comprising An IL-2 ConjugateApplication 63214634Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .